Market Cap : 16.74 B | Enterprise Value : 13.78 B | PE Ratio : 17.71 | PB Ratio : 4.09 |
---|
NAS:INCY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:INCY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Good Sign:
Altman Z-score of 9.48 is strong.
Incyte has a Altman Z-Score of 9.61, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Incyte's Altman Z-Score or its related term are showing as below:
During the past 13 years, Incyte's highest Altman Z-Score was 28.74. The lowest was -11.01. And the median was 6.55.
The historical data trend for Incyte's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Incyte's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Incyte's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Incyte's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Incyte's Altman Z-Score for today is calculated with this formula:
Z | = | 1.2 | * | X1 | + | 1.4 | * | X2 | + | 3.3 | * | X3 | + | 0.6 | * | X4 | + | 1.0 | * | X5 |
= | 1.2 | * | 0.5075 | + | 1.4 | * | -0.1088 | + | 3.3 | * | 0.1188 | + | 0.6 | * | 13.5696 | + | 1.0 | * | 0.6243 | |
= | 9.61 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Trailing Twelve Months (TTM) ended in Jun. 2022:
Total Assets was $5,319 Mil.
Total Current Assets was $3,626 Mil.
Total Current Liabilities was $927 Mil.
Retained Earnings was $-578 Mil.
Pre-Tax Income was 229.378 + 70.535 + 120.02 + 209.469 = $629 Mil.
Interest Expense was -0.678 + -0.68 + -0.752 + -0.439 = $-3 Mil.
Revenue was 911.397 + 733.235 + 862.853 + 812.987 = $3,320 Mil.
Market Cap (Today) was $16,745 Mil.
Total Liabilities was $1,234 Mil.
* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.
X1 | = | Working Capital | / | Total Assets |
= | (Total Current Assets - Total Current Liabilities) | / | Total Assets | |
= | (3625.845 - 926.674) | / | 5319.035 | |
= | 0.5075 |
X2 | = | Retained Earnings | / | Total Assets |
= | -578.45 | / | 5319.035 | |
= | -0.1088 |
X3 | = | Earnings Before Interest and Taxes | / | Total Assets |
= | (Pre-Tax Income - Interest Expense) | / | Total Assets | |
= | (629.402 - -2.549) | / | 5319.035 | |
= | 0.1188 |
X4 | = | Market Value Equity | / | Book Value of Total Liabilities |
= | Market Cap | / | Total Liabilities | |
= | 16744.578 | / | 1233.974 | |
= | 13.5696 |
X5 | = | Revenue | / | Total Assets |
= | 3320.472 | / | 5319.035 | |
= | 0.6243 |
The zones of discrimination were as such:
Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones
Incyte has a Altman Z-Score of 9.61 indicating it is in Safe Zones.
Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Read more about Altman Z-Score and the original research.
Altman Z-Score does not apply to financial companies.
Thank you for viewing the detailed overview of Incyte's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Tray Thomas | officer: Principal Accounting Officer | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Brawley Otis W | director | 5203 BRISTOL INDUSTRIAL WAY BUFORD GA 30518 |
High Katherine A | director | 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104 |
Harrigan Edmund | director | |
Morrissey Michael James | officer: EVP, Head of Tech. Operations | IN CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803 |
Dickinson Jonathan Elliott | officer: EVP, General Manager, Europe | CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803 |
Stamoulis Christiana | officer: EVP & Chief Financial Officer | C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139 |
Dhanak Dashyant | officer: EVP & Chief Scientific Officer | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Pasquale Maria E | officer: EVP & General Counsel | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Fouse Jacqualyn A | director | C/O DICK'S SPORTING GOODS 345 COURT STREET CORAOPOLIS PA 15108 |
Iyengar Vijay K | officer: EVP GPS, BD, & Licensing | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Stein Steven H | officer: EVP & Chief Medical Officer | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Trower Paul | officer: VP, Finance & Prin Acc Officer | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Clancy Paul J | director | C/O BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 |
Bienaime Jean Jacques | director | 925 PAGE MILL ROAD PALO ALTO CA 94304 |
From GuruFocus
Other Sources
By tipranks.com 2022-03-14
By Zacks 2021-12-06
By tipranks.com 2022-02-08
By tipranks.com 2022-02-11
By Zacks 2022-03-10
By Zacks 2022-01-27
By Zacks 2021-12-16
By Seekingalpha 2022-01-24
By Zacks 2022-01-17
By Zacks 2022-01-10
By Seekingalpha 2021-12-28
By Zacks 2022-02-03
By tipranks.com 2022-03-27
By tipranks.com 2022-02-10
By Zacks 2022-02-03